Alan Bryce discusses PT-112, a platinum-containing drug with immunogenic cell death mechanism and osteotropic properties, with Oliver Sartor. The phase-two dose-finding study enrolled heavily ...
Patient Out-of-Pocket Costs for Guideline-Recommended Treatments for Erectile Dysfunction: A Medicare Cost Modeling Analysis - Beyond the Abstract ...
Transdermal Application of H100 Gel to the Penile Shaft in Patients with Peyronie's Disease Infiltrates the Tunica Albuginea - Beyond the Abstract ...
Is Primary Retroperitoneal Lymph Node Dissection the Way Forward for Patients with Testicular Seminoma and Limited Retroperitoneal Metastases? - Beyond the Abstract ...
Relationship Between the Frequency of Electrocautery of Hunner Lesions and Changes in Bladder Capacity in Patients with Hunner Type Interstitial Cystitis - Beyond the Abstract ...
Robotic/laparoscopic prolapse repair and the role of hysteropexy: A urology perspective, "Beyond the Abstract," by Daniel S. Elliott, MD ...
Chronic prostatitis/chronic pelvic pain syndrome: Interplay of inflammatory mediators, "Beyond the Abstract," by Dan Lundh, Hans Hedelin, and Dennis Larsson ...
Robotic versus Open Cystectomy with Ileal Conduit for the Management of Neurogenic Bladder: A Comparative Study - Beyond the Abstract ...
Assessment of miRNA 106a-5p and 375-3p Expression in the Context of the Wnt/β-Catenin Pathway-Comparison of Prostate Adenocarcinoma and Benign Prostatic Hyperplasia Tissues. Pine-Extracted Phytosterol ...
Measurement of patients' acceptable symptom levels and priorities for symptom improvement in advanced prostate cancer. January 6, 2026 Results of the Randomized Phase 3 AFU-GETUG-20 Trial Evaluating ...
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Jason Efstathiou about the results of the PARTIQoL Trial, a Phase III study comparing proton beam therapy to IMRT for localized prostate cancer. Dr. Efstathiou reveals that the study found no ...